EN DE
STOCK COMPARISON

Caregen Co.Ltd vs Shukra Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Caregen Co.Ltd (214370) and Shukra Pharmaceuticals (SHUKRAPHAR) compare, as of Sep 24, 2026.

As of Sep 24, 2026, Fair Value Calculator sees Caregen Co.Ltd as the less overvalued of the two: Caregen Co.Ltd trades at KRW 40,200 versus a fair value of KRW 6,352 (-84%), while Shukra Pharmaceuticals trades at ₹58.73 versus ₹9.09 (-85%).
Caregen Co.Ltd
214370.KQ · KRW · Health Care
-84%
upside to fair value
overvalued
PriceKRW 40,200
Fair ValueKRW 6,352
Quality72/100
Shukra Pharmaceuticals
SHUKRAPHAR.BSE · INR · Health Care
-85%
upside to fair value
overvalued
Price₹58.73
Fair Value₹9.09
Quality53/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

Caregen Co.LtdShukra Pharmaceuticals
Valuation
n/aP/E (TTM)75.3×
0.03×P/S (TTM)34.35×
n/aP/B28.62×
n/aEV/EBITDA51.0×
−84.2%Fair value upside−84.5%
2.1%Dividend yield0.0%
n/aDividend per share₹0.01
Profitability
46%Operating margin79%
0.53×EBIT margin trend (5Y)21.24×
n/aReturn on equity29%
8%Return on assets18%
Growth
34%Revenue growth (YoY)336%
1.8%Avg. growth/yr (3Y)-1.2%
3.8%Avg. growth/yr (5Y)38.3%
−30.0%Value creation/yr+51.8%
Balance & size
n/aInterest coverage (EBIT/interest)23.1×
n/aDebt / equity0.04×
$2BMarket cap$267M
mixedGrowth qualityexpensive

Even match: 5 to 5 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Caregen Co.Ltdof which business quality 67 · market factors 21 Shukra Pharmaceuticalsof which business quality 51 · market factors 83
ProfitabilityMargins and returns on capital today
51
75
Quality GrowthAre margins and returns improving?
34
79
CashflowEarnings quality: real cash, not paper profit
65
9
Fin. StrengthBalance sheet, leverage, solvency risk
83
83
InvestmentDisciplined investing over empire-building
91
6
Low VolatilityCalm price path (market factor)
50
51
MomentumPrice trend over the last 3–12 months (market factor)
12
97
52W MomentumDistance to the 52-week high (market factor)
4
96
Net IssuanceShare count: buybacks or dilution?
84
40

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyCaregen Co.LtdPrice KRW 40,200Shukra PharmaceuticalsPrice ₹58.73
DCF Models-84%below the priceKRW 6,553-85%below the price₹8.84
Earnings-Based-92%below the priceKRW 3,071-70%below the price₹17.63
Dividend Discount-74%below the priceKRW 10,462n/a
Multiples-82%below the priceKRW 7,134-85%below the price₹8.91
Asset-Based-93%below the priceKRW 2,913-98%below the price₹1.37
Growth DCF-88%below the priceKRW 4,874n/a
Economic Profit-91%below the priceKRW 3,664-87%below the price₹7.87
Growth Earnings-82%below the priceKRW 7,396-60%below the price₹23.40
Minimum-93%below the priceKRW 2,913-98%below the price₹1.37
Maximum-74%below the priceKRW 10,462-60%below the price₹23.40
Median-86%below the priceKRW 5,713-85%below the price₹8.87
Geometric mean-87%below the priceKRW 5,251-86%below the price₹8.40

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Caregen Co.Ltd: 25 of 25 models see the stock below the current price.

Shukra Pharmaceuticals: 15 of 15 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Caregen Co.Ltd
Price KRW 40,200
Fair Value KRW 6,352
Bear KRW 4,135Bull KRW 9,052
Shukra Pharmaceuticals
Price ₹58.73
Fair Value ₹9.09
Bear ₹6.80Bull ₹19.88

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Caregen Co.Ltd · Health Care

Quality score72 · Top 25%
Fair value upside-84% · bottom 25%

Shukra Pharmaceuticals · Health Care

Quality score53 · above median
Fair value upside-85% · bottom 25%

Bottom line

As of Sep 24, 2026, Fair Value Calculator sees Caregen Co.Ltd as the less overvalued of the two: Caregen Co.Ltd trades at KRW 40,200 versus a fair value of KRW 6,352 (-84%), while Shukra Pharmaceuticals trades at ₹58.73 versus ₹9.09 (-85%).

Caregen Co.Ltd has the higher quality score (72/100).

Open Caregen Co.Ltd live analysis →
Caregen Co.Ltd · Shukra Pharmaceuticals

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Caregen Co.Ltd

Microsoft vs NvidiaApple vs MicrosoftNvidia vs Taiwan Semiconductor ManufacturingApple vs Taiwan Semiconductor Manufacturing

Related to Shukra Pharmaceuticals

Alphabet Inc Class C vs Meta PlatformsCisco Systems vs NvidiaMicrosoft vs Taiwan Semiconductor ManufacturingApple vs Cisco Systems
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.